Ongoing growth in revenue both domestically and internationally; Successful European sales meetings highlight strong demand
abroad; Continued progress with FDA
CHESTER, NY / ACCESSWIRE / December 27, 2016 / Repro Med Systems, Inc. dba RMS Medical Products (OTCQX: REPR) today announced
its financial results for the third quarter of the fiscal year ending February 28, 2017.
For the quarter ended November 30, 2016, net revenues were $3,193,113, an increase of 1.5% compared with $3,144,954 in the same
quarter last year. This also represents an increase of 1.4% versus the last quarter.
For the nine months ended November 30, 2016, net revenues were $9,331,208, an increase of 4.4% compared with $8,941,676 for the
same period last year, driven by increased sales of our infusion products to existing customers, as well as the addition of new
customers. Excluding non-recurring clinical trial work in 2015, core revenue is up 6.5% for the most recent nine months.
For the three months ended November 30, 2016, gross profit was $2,063,943 compared with $2,109,279 for the same period last
year. This decrease in the quarter was mostly driven by the increases in sales rebates related to a specific customer contract
renewal compared to the same period last year, as well as an increase in salary and related costs associated with increased
staffing in our quality department to facilitate compliance with our quality management system. RMS continues benefiting from lean
manufacturing initiatives, which have increased capacity and decreased direct assembly labor costs, as well as the effects of a
moratorium on the medical device tax. For the nine months ended November 30, 2016, our gross profit margin increased to 63.8%, up
from 63.0% for the same period last year. Gross profit for the nine months ended November 30, 2016 was $5,955,346 compared with
$5,633,868 for the comparable period last year.
RMS continues to incur professional fees related to regulatory and litigation and has made significant investment over the last
nine months in its sales, regulatory, quality, and operations management, including hiring a Chief Medical Officer, to help launch
RMS to the next level of growth. As a result, the Company reported for this quarter ended November 30, a net loss of $104,275,
compared to net income of $167,552 in the same period last year. For the nine months ended November 30, 2016, net loss was $420,204
compared with net income of $438,126 for the same period last year.
Excluding consulting and professional fees related to regulatory and litigation (summarized in the attached tables), net income
for the quarter ended November 30, 2016 would have been $281,197 compared with $352,694 for the same period last year. For the nine
months ended November 30, 2016, net income would have been $573,245 compared with $780,926 last year. Non-GAAP EBITDA for the
quarter would have been $509,310 compared to $603,658 for last year and for the nine months would have been $1,095,662 compared
with $1,387,308 for the same period last year.
Andy Sealfon, RMS CEO and President, commented, "We are pleased to see some of our efforts internationally starting to come
through with orders." Addressing the FDA Warning Letter, Mr. Sealfon noted: "We continue to work closely with the FDA in order to
resolve the FDA Warning Letter. We have been and will continue to be proactive in working with the agency in order to resolve all
issues that have been or may be raised by the agency as soon as possible."
In the upcoming months, RMS plans to be participating in a number of distributor sales meetings, giving the Company the
opportunity to speak with its customers and align corporate goals for 2017. In addition, RMS launched its redesigned website
enhanced with search engine optimization and other analytics. As patients, providers, and distributors look to the web for better
resources regarding product information, best practices and continuous improvement, we plan to make developments continuously to
the site to further enhance the visitor experience and interaction with the RMS brand.
The Company manufactures medical products used for infusions and suctioning. The Infusion product portfolio currently includes
the FREEDOM60® and our latest FreedomEdge® Syringe Infusion Pumps, RMS Precision Flow Rate Tubing™ and RMS HIgH-Flo™ Subcutaneous
Safety Needle Sets. These devices are used for infusions administered in professional healthcare settings as well as at home. The
Company's RES-Q-VAC® line of medical suctioning products is used by emergency medical service providers in addition to a variety of
other healthcare providers.
The Company's website may be visited at www.rmsmedicalproducts.com.
This press release includes "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange Act of 1934, as amended. In addition to statements which explicitly describe
such risks and uncertainties, readers are urged to consider statements labeled with the terms "believes", "belief," "expects,"
"intends," "anticipates," "will," or "plans" to be uncertain and forward-looking. The forward-looking statements contained herein
are also subject generally to other risks and uncertainties that are described from time to time in the Company's reports and
registration statements filed with the Securities and Exchange Commission.
This press release includes non-GAAP financial measures that are not in accordance with, nor an alternate to, generally accepted
accounting principles and may be different from non-GAAP measures used by other companies. In addition, these non-GAAP measures are
not based on any comprehensive set of accounting rules or principles. Non-GAAP financial measures should not be considered a
substitute for, or superior to, measures of financial performance prepared in accordance with GAAP. They are limited in value
because they exclude charges that have a material effect on our reported results and, therefore, should not be relied upon as the
sole financial measures to evaluate our financial results. The non-GAAP financial measures are meant to supplement, and to be
viewed in conjunction with, GAAP financial results. A reconciliation of our non-GAAP measures is included in an attachment to this
press release.
For more information please call:
Mike King 702 650 3000 Princeton Research
SELECTED FINANCIAL RESULTSFor the Three Months Ended For the Nine Months Ended
November 30 November 30 2016 2015 2016 2015 NET SALES $ 3,193,113 $ 3,144,954 $ 9,331,208 $ 8,941,676 Cost of goods sold 1,129,170
1,035,675 3,375,862 3,307,808 Gross Profit 2,063,943 2,109,279 5,955,346 5,633,868 OPERATING EXPENSES Selling, general and
administrative 2,034,016 1,698,226 6,145,769 4,567,709 Research and development 59,142 51,564 183,497 143,940 Depreciation and
amortization 83,254 69,274 227,109 204,087 Total Operating Expenses 2,176,412 1,819,064 6,556,375 4,915,736 Net Operating
(Loss)/Profit (112,469 ) 290,215 (601,029 ) 718,132 Non-Operating (Expense)/Income Loss on currency exchange (43,546 ) (36,663 )
(33,802 ) (42,420 ) Loss on disposal of fixed assets — (253 ) (1 ) (13,577 ) Interest expense (1,930 ) — (1,886 ) — Interest and
other income 454 929 1,549 3,058 TOTAL OTHER (EXPENSES) INCOME (45,022 ) (35,987 ) (34,140 ) (52,939 ) (LOSS) INCOME BEFORE TAXES
(157,491 ) 254,228 (635,169 ) 665,193 Income Tax Benefit (Expense) 53,216 (86,676 ) 214,965 (227,067 ) NET (LOSS) INCOME $ (104,275
) $ 167,552 $ (420,204 ) $ 438,126 NET (LOSS)/INCOME PER SHARE Basic $ — $ — $ (0.01 ) $ 0.01 Diluted $ — $ — $ (0.01 ) $ 0.01
WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING Basic 37,746,731 38,006,667 37,857,074 38,006,667 Diluted 37,794,350
38,006,667 37,904,693 38,006,667 Reconciliation of GAAP Net (Loss)/Income Three Months Ended November 30 Nine Months Ended November
30 to Non-GAAP Normalized EBITDA: 2016 2015 2016 2015 GAAP Net (Loss)/Income $ (104,275 ) $ 167,552 $ (420,204 ) $ 438,126 Tax
(Benefit)/Expense (53,216 ) 86,676 (214,965 ) 227,067 Depreciation 83,254 69,274 227,109 204,087 Professional Fees (1) 583,547
280,156 1,503,722 518,028 Non-GAAP Normalized EBITDA $ 509,310 $ 603,658 $ 1,095,662 $ 1,387,308 Reconciliation of GAAP Net
(Loss)/Income to Non-GAAP Normalized Net Income: 2016 2015 2016 2015 GAAP Net (Loss)/Income $ (104,275 ) $ 167,552 $ (420,204 ) $
438,126 Professional Fees (1) 583,547 280,156 1,503,722 518,028 Tax Expense on Professional Fees (198,075 ) (95,014 ) (510,273 )
(175,228 ) Non-GAAP Normalized Net Income $ 281,197 $ 352,694 $ 573,245 $ 780,926
1. Includes consulting and professional fees related to regulatory and litigation.
SOURCE: RMS Medical Products
